TW201722422A - 用於治療癌症之合理組合療法 - Google Patents

用於治療癌症之合理組合療法 Download PDF

Info

Publication number
TW201722422A
TW201722422A TW105132272A TW105132272A TW201722422A TW 201722422 A TW201722422 A TW 201722422A TW 105132272 A TW105132272 A TW 105132272A TW 105132272 A TW105132272 A TW 105132272A TW 201722422 A TW201722422 A TW 201722422A
Authority
TW
Taiwan
Prior art keywords
cancer
protein
hsp90
administered
inhibitor
Prior art date
Application number
TW105132272A
Other languages
English (en)
Chinese (zh)
Inventor
蓋比拉 齊席斯
東尼 塔爾頓
麗莎 雪沙塔
約翰 可倫
艾瑞卡 達加瑪 果美斯
安娜 羅迪那
Original Assignee
美國紀念斯隆-凱特琳癌症中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國紀念斯隆-凱特琳癌症中心 filed Critical 美國紀念斯隆-凱特琳癌症中心
Publication of TW201722422A publication Critical patent/TW201722422A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW105132272A 2015-10-05 2016-10-05 用於治療癌症之合理組合療法 TW201722422A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05

Publications (1)

Publication Number Publication Date
TW201722422A true TW201722422A (zh) 2017-07-01

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105132272A TW201722422A (zh) 2015-10-05 2016-10-05 用於治療癌症之合理組合療法

Country Status (14)

Country Link
US (1) US20180280397A1 (enExample)
EP (1) EP3359196B1 (enExample)
JP (1) JP7132848B2 (enExample)
KR (1) KR20180058824A (enExample)
CN (1) CN108472376A (enExample)
AU (1) AU2016336351A1 (enExample)
BR (1) BR112018006572A2 (enExample)
CA (1) CA3000851A1 (enExample)
EA (1) EA201890623A1 (enExample)
IL (1) IL258494A (enExample)
MA (1) MA47474A (enExample)
MX (1) MX2018004112A (enExample)
TW (1) TW201722422A (enExample)
WO (1) WO2017062520A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882783B (zh) * 2023-05-02 2025-05-01 國立中央大學 偵測轉譯後修飾之方法、系統及電腦可讀取媒體

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016008418A (es) 2013-12-23 2017-01-11 Memorial Sloan Kettering Cancer Center Metodos y reactivos para el radiomarcaje.
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
CN116813622B (zh) * 2023-05-19 2026-02-03 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004512381A (ja) 2000-11-02 2004-04-22 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
PT2486039T (pt) 2009-10-07 2016-09-06 Sloan Kettering Inst For Cancer Res Derivados de purina úteis como inibidores de hsp90
AU2012240077C1 (en) 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
MX354215B (es) 2011-04-05 2018-02-19 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2624982T3 (es) 2011-07-08 2017-07-18 Sloan-Kettering Institute For Cancer Research Usos de inhibidores etiquetados HSP90
KR102319582B1 (ko) 2013-08-16 2021-11-04 메모리얼 슬로안 케터링 캔서 센터 선택적 ｇｒｐ９４ 저해제 및 이의 용도
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882783B (zh) * 2023-05-02 2025-05-01 國立中央大學 偵測轉譯後修飾之方法、系統及電腦可讀取媒體

Also Published As

Publication number Publication date
EP3359196B1 (en) 2022-03-16
MA47474A (fr) 2019-12-25
EP3359196A1 (en) 2018-08-15
WO2017062520A1 (en) 2017-04-13
CA3000851A1 (en) 2017-04-13
BR112018006572A2 (pt) 2018-10-09
EA201890623A1 (ru) 2018-09-28
JP7132848B2 (ja) 2022-09-07
MX2018004112A (es) 2018-06-20
JP2018537519A (ja) 2018-12-20
IL258494A (en) 2018-05-31
US20180280397A1 (en) 2018-10-04
KR20180058824A (ko) 2018-06-01
AU2016336351A1 (en) 2018-05-10
CN108472376A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
Halder et al. Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
US20230330243A1 (en) Combination of antibody-drug conjugate and atr inhibitor
TW202216209A (zh) 抗體-藥物結合物及atm抑制劑之組合
TW201032796A (en) Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
KR20180035905A (ko) Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
JP7132848B2 (ja) 癌の治療のための合理的併用療法
BR112017015576A2 (en) method for cancer treatment, article, method for monitoring, method for optimizing therapeutic efficacy, method for identifying a biomarker, use, therapeutic combination, combination for use and product
Zhou et al. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer
Liu et al. SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells: SY-707 is an ALK/FAK/IGF1R inhibitor
CN113939297A (zh) 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
US20250339549A1 (en) Methods for the detection and treatment of non-small-cell lung cancer
WO2025082484A1 (zh) 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
CN121969391A (zh) 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症
Huang et al. Synergistic antitumor activity of pro‐apoptotic agent PAC‐1 with cisplatinum by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299
US9566334B2 (en) Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
EP4582104A1 (en) Combination drug
HK1259690A1 (en) Rational combination therapy for the treatment of cancer
HK1259690B (en) Rational combination therapy for the treatment of cancer
Knickelbein Mechanisms and Novel Therapeutic Approaches for KRAS-Mediated Resistance to Anti-EGFR Therapy in Colorectal Cancer Cells
Stanley Exploiting Novel Interactions With Parp1 In Dna Repair Proficient Human Breast Cancers
Gerrard Modulation of P-glycoprotein by Zosuquidar Trihydrochloride
Millard Discovery of novel small molecules targeting cancer cell metabolism